Effect of immediate vs gradual reduction in nicotine content of cigarettes on biomarkers of smoke exposure a randomized clinical trial

JAMA - Journal of the American Medical Association

Volumn 320, Issue 9, 2018, Pages 880-891

  Hatsukami, Dorothy K ^a   Luo, Xianghua ^a   Jensen, Joni A ^a   Al'Absi, Mustafa ^b   Allen, Sharon S ^b   Carmella, Steven G ^a   Chen, Menglan ^a   Cinciripini, Paul M ^c   Denlinger Apte, Rachel ^d   Drobes, David J ^e   Koopmeiners, Joseph S ^a   Lane, Tonya ^a   Le, Chap T ^a   Leischow, Scott ^f   Luo, Kai ^a   Joseph McClernon, F ^g   Murphy, Sharon E ^a   Paiano, Viviana ^a   Robinson, Jason D ^c   Severson, Herbert ^h   Sipe, Christopher ^a   Strasser, Andrew A ⁱ   Strayer, Lori G ^a   Tang, Mei Kuen ^a   Vandrey, Ryan ^j   Hecht, Stephen S ^a   Benowitz, Neal L ^k   Donny, Eric C ^l   more..

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d BROWN UNIVERSITY   (United States)

^e H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^f MAYO CLINIC   (United States)

^g DUKE UNIVERSITY   (United States)

^h OREGON RESEARCH INSTITUTE   (United States)

ⁱ UNIVERSITY OF PENNSYLVANIA   (United States)

^j JOHNS HOPKINS UNIVERSITY   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

^l WAKE FOREST SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYPROPYLMERCAPTURIC ACID; ACETYLCYSTEINE DERIVATIVE; ACROLEIN; CARBON MONOXIDE; CIGARETTE SMOKE; NICOTINE; PHENANTHRENE TETRAOL; POLYCYCLIC AROMATIC HYDROCARBON; UNCLASSIFIED DRUG; ACETYLCYSTEINE; BIOLOGICAL MARKER; CREATININE; PHENANTHRENE DERIVATIVE; S-(3-HYDROXYPROPYL)CYSTEINE N-ACETATE;

ADULT; ARTICLE; BREAST FEEDING; CONTROLLED STUDY; CRAVING; DIASTOLIC BLOOD PRESSURE; FEMALE; FOLLOW UP; GRADUAL SMOKING REDUCTION; HUMAN; IMMEDIATE SMOKING REDUCTION; INTERVENTION STUDY; MALE; PRIORITY JOURNAL; SMOKING; SMOKING REDUCTION; SYSTOLIC BLOOD PRESSURE; TOBACCO USE; UNITED STATES; WITHDRAWAL SYNDROME; ANALOGS AND DERIVATIVES; ANALYSIS; AREA UNDER THE CURVE; BREATH ANALYSIS; CLINICAL TRIAL; COMPARATIVE STUDY; DOUBLE BLIND PROCEDURE; MIDDLE AGED; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SMOKE; SMOKING CESSATION; STATISTICS AND NUMERICAL DATA; TOBACCO; TOBACCO DEPENDENCE; URINE;

ACETYLCYSTEINE; ADULT; AREA UNDER CURVE; BIOMARKERS; BREATH TESTS; CARBON MONOXIDE; CREATININE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NICOTINE; PHENANTHRENES; SMOKE; SMOKING CESSATION; SUBSTANCE WITHDRAWAL SYNDROME; TOBACCO; TOBACCO PRODUCTS; TOBACCO USE DISORDER;

EID: 85053007235     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2018.11473     Document Type: Article

References (42)

1. US Department of Health and Human Services. How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease: A Report of the Surgeon General. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2010.
2. US Department of Health and Human Services. The Health Consequences of Smoking-50 Years of Progress: A Report of the Surgeon General. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2014.
3. US Department of Health and Human Services. The Health Consequences of Smoking: Nicotine and Addiction: A Report of the Surgeon General: DHHS Publication No. (CDC) 88-8406. Washington, DC: US Department of Health and Human Services; 1988.
4. Food and Drug Administration. Tobacco Product Standard for Nicotine Level of Combusted Cigarettes: 83 FR 11818. Washington, DC: Federal Register; 2018:11818-11843.
5. Apelberg BJ, Feirman SP, Salazar E, et al. Potential public health effects of reducing nicotine levels in cigarettes in the United States. N Engl J Med. 2018;378(18):1725-1733. doi:10.1056/NEJMsr1714617
6. National Institute on Drug Abuse. Nicotine Research Cigarettes Drug Supply Program. https://www.drugabuse.gov/nicotine-research-cigarette-drug-supply-program. Revised January 2016. Accessed January 17, 2018.
7. Kozlowski LT, Mehta NY, Sweeney CT, et al. Filter ventilation and nicotine content of tobacco in cigarettes from Canada, the United Kingdom, and the United States. Tob Control. 1998;7(4):369-375. doi:10.1136/tc.7.4.369
8. Donny EC, Denlinger RL, Tidey JW, et al. Randomized trial of reduced-nicotine standards for cigarettes. N Engl J Med. 2015;373(14):1340-1349. doi:10.1056/NEJMsa1502403
9. R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2017.
10. Denlinger RL, Smith TT, Murphy SE, et al. Nicotine and anatabine exposure from very low nicotine content cigarettes. Tob Regul Sci. 2016;2 (2):186-203. doi:10.18001/TRS.2.2.9
11. Henning RJ, Johnson GT, Coyle JP, Harbison RD. Acrolein can cause cardiovascular disease: a review. Cardiovasc Toxicol. 2017;17(3):227-236. doi:10.1007 /s12012-016-9396-5
12. Haussmann HJ. Use of hazard indices for a theoretical evaluation of cigarette smoke composition. Chem Res Toxicol. 2012;25(4):794-810. doi:10.1021/tx200536w
13. Carmella SG, Ming X, Olvera N, Brookmeyer C, Yoder A, Hecht SS. High throughput liquid and gas chromatography-tandem mass spectrometry assays for tobacco-specific nitrosamine and polycyclic aromatic hydrocarbon metabolites associated with lung cancer in smokers. Chem Res Toxicol. 2013;26(8):1209-1217. doi:10.1021/tx400121n
14. Carmella SG, Chen M, Zarth A, Hecht SS. High throughput liquid chromatography-tandem mass spectrometry assay for mercapturic acids of acrolein and crotonaldehyde in cigarette smokers' urine. J Chromatogr B Analyt Technol Biomed Life Sci. 2013;935:36-40. doi:10.1016/j.jchromb.2013.07.004
15. Zarth AT, Carmella SG, Le CT, Hecht SS. Effect of cigarette smoking on urinary 2-hydroxypropylmercapturic acid, a metabolite of propylene oxide. J Chromatogr B Analyt Technol Biomed Life Sci. 2014;953-954:126-131. doi:10.1016/j.jchromb.2014.02.001
16. Carmella SG, Chen M, Han S, et al. Effects of smoking cessation on eight urinary tobacco carcinogen and toxicant biomarkers. Chem Res Toxicol. 2009;22(4):734-741. doi:10.1021/tx800479s
17. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict. 1991;86(9): 1119-1127. doi:10.1111/j.1360-0443.1991.tb01879.x
18. Smith SS, Piper ME, Bolt DM, et al. Development of the Brief Wisconsin Inventory of Smoking Dependence Motives. Nicotine Tob Res. 2010;12(5):489-499. doi:10.1093/ntr/ntq032
19. Hughes JR, Hatsukami D. Signs and symptoms of tobacco withdrawal. Arch Gen Psychiatry. 1986;43(3):289-294. doi:10.1001/archpsyc.1986.01800030107013
20. Cox LS, Tiffany ST, Christen AG. Evaluation of the brief Questionnaire of Smoking Urges (QSU-brief) in laboratory and clinical settings. Nicotine Tob Res. 2001;3(1):7-16. doi:10.1080 /14622200020032051
21. Watson D, Clark LA, Tellegen A. Development and validation of brief measures of positive and
22. negative affect: the PANAS scales. J Pers Soc Psychol. 1988;54(6):1063-1070. doi:10.1037/0022-3514.54.6.1063
23. Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. J Health Soc Behav. 1983;24(4):385-396. doi:10.2307/2136404
24. Radloff LS. The CES-D Scale: a self-report depression scale for research in the general population. Appl Psychol Meas. 1977;1(3):385-401. doi:10.1177/014662167700100306
25. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale, NJ: L Erlbaum Associates; 1988.
26. Sawilowsky S. New effect size rules of thumb. J Mod Appl Stat Methods. 2009;8(2):597-599. doi:10.22237/jmasm/1257035100
27. Little RJA, Rubin DB. Statistical Analysis With Missing Data. 2nd ed. Hoboken, NJ: Wiley; 2002. doi:10.1002/9781119013563
28. Schafer JL. Analysis of Incomplete Multivariate Data. New York, NY: Chapman & Hall; 1997. doi:10.1201/9781439821862
29. Molenberghs G, Kenward M. Missing Data in Clinical Studies. Vol 61. Chichester, UK: John Wiley & Sons; 2007. doi:10.1002/9780470510445
30. Allenby CE, Boylan KA, Lerman C, Falcone M. Precision medicine for tobacco dependence: development and validation of the nicotine metabolite ratio. J Neuroimmune Pharmacol. 2016; 11(3):471-483. doi:10.1007/s11481-016-9656-y
31. National Institute on Drug Abuse Clinical Trials Network. Common Data Elements: the Fagerstrom Test for Nicotine Dependence (FTND). https://cde.drugabuse.gov/instrument/d7c0b0f5 -b865-e4de-e040-bb89ad43202b. Accessed July 10, 2018.
32. Zich JM, Attkisson CC, Greenfield TK. Screening for depression in primary care clinics: the CES-D and the BDI. Int J Psychiatry Med. 1990;20(3):259-277. doi:10.2190/LYKR-7VHP-YJEM-MKM2
33. Ensel WM. Measuring depression: The CES-D scale. In: Dean A, Ensel WM, Lin N, eds. Social
34. Support, Life Events, and Depression. Minneapolis, MN: Academic Press, Inc; 1986:51-70. doi:10.1016 /B978-0-12-450660-2.50011-2
35. Hatsukami DK, Kotlyar M, Hertsgaard LA, et al. Reduced nicotine content cigarettes: effects on toxicant exposure, dependence and cessation. Addiction. 2010;105(2):343-355. doi:10.1111/j.1360 -0443.2009.02780.x
36. Hatsukami DK, Hertsgaard LA, Vogel RI, et al. Reduced nicotine content cigarettes and nicotine patch. Cancer Epidemiol Biomarkers Prev. 2013;22 (6):1015-1024. doi:10.1158/1055-9965.EPI-12-1439
37. Benowitz NL, Dains KM, Hall SM, et al. Smoking behavior and exposure to tobacco toxicants during 6 months of smoking progressively reduced nicotine content cigarettes. Cancer Epidemiol Biomarkers Prev. 2012;21(5):761-769. doi:10.1158 /1055-9965.EPI-11-0644
38. Mercincavage M, Souprountchouk V, Tang KZ, et al. A randomized controlled trial of progressively reduced nicotine content cigarettes on smoking behaviors, biomarkers of exposure, and subjective ratings. Cancer Epidemiol Biomarkers Prev. 2016;25 (7):1125-1133. doi:10.1158/1055-9965.EPI-15-1088
39. International Agency for Research on Cancer. Tobacco Smoking. In: IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol 100E. Lyon, France: International Agency for Research on Cancer, World Health Organization; 2012:43-212.
40. Thun MJ, Carter BD, Feskanich D, et al. 50-year trends in smoking-related mortality in the United States. N Engl J Med. 2013;368(4):351-364. doi:10.1056/NEJMsa1211127
41. Hatsukami DK, Luo X, Dick L, et al. Reduced nicotine content cigarettes and use of alternative nicotine products: exploratory trial. Addiction. 2017; 112(1):156-167. doi:10.1111/add.13603
42. Benowitz NL, Donny EC, Hatsukami DK. Reduced nicotine content cigarettes, e-cigarettes and the cigarette end game. Addiction. 2017;112(1): 6-7. doi:10.1111/add.13534